Victory Square Technologies Inc

Victory Square Technologies Inc

0.29
EUR
+0.00
(-1.38%)
0.05EPS
12.71P/E
43.69MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
0.01
0.06
0.05
0.02
0.02
0.06
0.12
0.17
0.35
0.77
Basic EPS, GAAP
-0.03
-0.06
-0.05
-0.18
-0.1
0.27
-0.15
-0.25
-0.14
0.01
0.02
0.05
Free Cash Flow per Basic Share
-0.03
-0.05
-0.03
-0.04
-0.04
-0.04
-0.09
-0.04
-0.03
-0.02
-0.05
-0.14
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.03
0.16
0.2
0.11
0.43
0.28
0.14
0.04
0.06
0.3
0.44
Tangible Book Value per Share
- -
-0.02
0.13
0.18
0.11
0.37
0.21
0.07
0.01
0.03
0.25
0.38
Basic Weighted Avg Shares
20
42
53
69
73
75
94
98
100
100
102
102
Sales/Revenue/Turnover
- -
- -
1
4
4
1
1
6
12
17
35
78
Operating Margin (%)
-1,645.71
-623.8
-384.24
-143.07
-78.53
-165.55
-944.09
-232.79
-84.88
-12.5
1.93
8.71
Depreciation Expense
- -
- -
1
2
1
1
3
3
3
1
1
1
Net Income, GAAP
-1
-3
-3
-13
-7
20
-14
-24
-14
1
2
5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,905.18
-626.78
-369.44
-284.43
-210.32
1,339.27
-927.03
-407.99
-117.42
7.38
5.75
6.99
Working Capital
- -
-1
2
3
-1
3
- -
-1
-6
-6
15
34
LT Debt
- -
- -
- -
- -
1
- -
1
5
4
- -
8
9
Total Equity
- -
1
10
16
9
39
31
13
- -
3
28
48
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-10.03
- -
- -
- -
- -
- -
20.21
Return on Capital (%)
- -
- -
- -
- -
- -
78.21
- -
- -
- -
- -
- -
13.93
Return on Common Equity (%)
- -
-295.47
-48.58
-105.63
-65.46
96.51
-45.93
-117
-157.97
24.45
11.04
19.34

Capital Structure

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
8
9
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
104
104
104
Market Capitalization
77
49
71

Working Capital

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
22
39
54
Cash, Cash Equivalents & STI
16
24
20
Accounts Receivable, Net
2
11
19
Inventories
- -
- -
- -
Total Current Liabilities
7
8
19
Payables & Accruals
4
4
17
ST Debt
- -
- -
- -
Deferred Revenue
2
3
2

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
87.76%
-66.98%
906.03%
Free Cash Flow
48.66%
45.48%
177.72%
Net Income, GAAP
6.96%
-36.02%
65.06%
Sales/Revenue/Turnover
214.27%
110.18%
111.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
4
5
4
17
2025
5
5
11
15
35
2026
25
28
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.02
0.11
-0.07
0.01
2025
-0.01
- -
0.01
0.01
0.02
2026
0.02
0.01
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shafin Diamond Tejani
Full Time Employees
2
Sector
Technology services
Industry
Information technology services
Address
800 – 1500 West Georgia Vancouver BC Canada V6G 2Z6
IPO Date
May 4, 2016
Business
Victory Square Technologies Inc. (CSE: VST, OTCQX: VSQTF) is a Vancouver-based venture builder and investor that builds, acquires and invests in early-stage startups focused on disruptive technologies; its portfolio of more than 25 companies spans sectors including artificial intelligence, blockchain, Web3, digital health, gaming, the creator economy, metaverse, virtual/augmented reality, climate tech, fintech, insurance and esports. The company provides senior leadership, operational resources and strategic support to accelerate portfolio growth and monetization, offering investors liquid exposure to high-potential tech ventures without traditional venture fund restrictions; key portfolio assets include Hydreight for at-home health services, VSDHOne for telehealth platforms, XR Immersive Tech for VR/AR solutions, Insu Therapeutics advancing oral insulin and continuous glucose monitoring technologies, and Pawsible Ventures developing pet wellness funds. Founded in 2015 and headquartered at 800-1500 West Georgia Street in Vancouver, Canada, with an additional office in Lewes, Delaware, Victory Square operates globally with a strong emphasis on ESG principles, supporting underrepresented entrepreneurs and community initiatives in youth, mental health and education. Recent developments include the October 2024 completion of a $1.7 million strategic transaction divesting BlockX Capital to Edge Total Intelligence Inc., receiving 4.25 million shares valued at approximately $3.95 million and forming EdgeAI Technologies Inc. to expand AI capabilities; Q3 2024 net income of $10.7 million; 33% year-over-year revenue growth to $13.9 million in H1 2025 driven by Hydreight's profitable quarters; and advancements such as Hydreight's nationwide expansion of at-home blood testing and VSDHOne's new asynchronous telehealth offerings in skincare, hair loss and sexual health.

Company News

  • Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

  • Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform

  • Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List

  • Victory Square Technologies Reports First-Half 2026 Revenue of $53.0 Million and Net Income of $6.5 Million

  • Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

  • Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

  • Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A

  • Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

  • Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances

  • Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

  • Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update

  • Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update

  • Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital

  • Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital

  • Hydreight Technologies Announces Timing of Q1 2026 Financial Results and Investor Webcast

  • Victory Square Technologies Reports Fiscal 2025 Results Highlighting Platform Scaling, Healthcare Infrastructure Growth and Portfolio Momentum

  • Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale

  • Comparing U-BX Technology (NASDAQ:UBXG) and Victory Square Technologies (OTCMKTS:VSQTF)

  • Hydreight Announces Normal Course Issuer Bid

  • Victory Square Provides Corporate Update on Healthcare Infrastructure Strategy and Portfolio Developments